Tight ship: CAPTN enlists IRB oversight

June 2009
Clinical Trials Administrator;Jun2009, Vol. 7 Issue 6, p70
The article considers the success of Duke University's Clinical Research Institute's (DCRI) Child and Adolescent Psychiatry Trials Network (CAPTN) to conduct studies about antidepressant safety in pediatric patients. According to Mark Shapiro, a management consultant who specializes in clinical research and drug development, a key factor to the project's success was the ability of the network creators to have several face-to-face meetings with the international review board (IRB). He claims that the team conduct about 10 meetings.


Related Articles

  • Data handling errors spur debate over clinical trial. Hutson, Stu // Nature Medicine;Jun2010, Vol. 16 Issue 6, p618 

    The article discusses the effects of data handling errors in clinical trials of biotechnological research. It mentions about the data errors made by researchers at Duke University in Durham, North Carolina, related chemotherapy for cancer patients. It further mentions that the error of...

  • Three-Pronged Approach to Optimizing Trial Monitoring. Mitchel, Jules T.; Cho, Timothy; Gittleman, Dean A.; Schloss Markowitz, Judith M.; Yong Joong Kim; Joonhyuk Choi; Hamrell, Michael R.; Nora, Sergio Dalla; Carrara, Dario // Applied Clinical Trials;Jun/Jul2014, Vol. 23 Issue 6/7, p37 

    The article discusses the three-pronged approach to optimize trial monitoring. The author talks about the publication of varied practices of monitoring clinical trials by the Clinical Trials Transformation Initiative (CTTI), a public-private partnership formally established in 2008 by the U.S....

  • Transition from congress abstract to full publication for clinical trials presented at laser meetings. Akbari-Kamrani, Marjan; Shakiba, Behnam; Parsian, Sana // Lasers in Medical Science;Sep2008, Vol. 23 Issue 3, p295 

    The present study aims to identify (1) what proportion of abstracts of clinical trials presented at The American Society for Laser Medicine and Surgery (ASLMS) annual meetings are published as full reports, (2) time to publication, and (3) factors that may predict the publication of research in...

  • A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy. O'Connor, Alec B.; Noyes, Katia; Holloway, Robert G. // PharmacoEconomics;2008, Vol. 26 Issue 12, p1045 

    Background: Painful diabetic neuropathy is common and adversely affects patients' quality of life and function. Several treatment options exist, but their relative efficacy and value are unknown. Objective: To determine the relative efficacy, costs and cost effectiveness of the first-line...

  • What Shapes Depressed Individuals' Pre-Treatment Expectation in Antidepressant Clinical Trials? Moses, Tally; Leuchter, Andrew F.; Cook, Ian; Abrams, Michelle // Internet Journal of Mental Health;2007, Vol. 3 Issue 2, p2 

    Objective: To examine the relationship between patients' treatment outcome expectation and a set of socio-demographic factors, clinical course variables, symptom severity, health locus of control, and Temperament and Character Inventory (TCI) dimensions. Method: Logistic regression analyses were...

  • How many good antidepressant medications have we missed? Blier, Pierre // Journal of Psychiatry & Neuroscience;Jul2004, Vol. 29 Issue 4, p248 

    This article focuses on antidepressant medications. Once antidepressant medications have been demonstrated to be safe for human use, they generally have to prove superior to placebo in at least 2 randomized, double-blind, placebo-controlled studies to be approved by regulatory agencies. It is...

  • Antidepressants: benefits overstated, harms understated?  // Reactions Weekly;4/24/2004, Issue 998, p4 

    Discusses research being done on guidelines for treating children with antidepressants. Reference to a study by J. N. Jureidini and colleagues, published in the April 10, 2004 issue of "BMI" journal; Involvement of pharmaceutical companies in the clinical trials reviewed; Conclusion of the...

  • An Open-Label Trial of Venlafaxine in Body Dysmorphic Disorder. Allen, Andrea; Jo Hadley, Sallie; Kaplan, Alicia; Simeon, Daphne; Friedberg, Jennifer; Priday, Lauren; Baker, Bryann R.; Greenberg, Jennifer L.; Hollander, Eric // CNS Spectrums: The International Journal of Neuropsychiatric Med;Feb2008, Vol. 13 Issue 2, p138 

    Objective: Body dysmorphic disorder (BDD), a preoccupation with imagined ugliness, is a disabling condition that seems to respond preferentially to selective serotonin reuptake inhibitors. This open-label trial examines venlafaxine's efficacy in BDD and is the first known study of this...

  • Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. de Bodinat, Christian; Guardiola-Lemaitre, Béatrice; Mocaër, Elisabeth; Renard, Pierre; Muñoz, Carmen; Millan, Mark J. // Nature Reviews Drug Discovery;Aug2010, Vol. 9 Issue 8, p628 

    Current management of major depression, a common and debilitating disorder with a high social and personal cost, is far from satisfactory. All available antidepressants act through monoaminergic mechanisms, so there is considerable interest in novel non-monoaminergic approaches for potentially...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics